CLINICAL TRIALS PROFILE FOR SAVOLITINIB

Clinical Trials for Savolitinib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02117167 ↗	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients	Active, not recruiting	AstraZeneca	Phase 2	Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as immunotherapy with maintenance therapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
NCT02117167 ↗	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients	Active, not recruiting	Fondation ARC	Phase 2	Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as immunotherapy with maintenance therapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
NCT02117167 ↗	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients	Active, not recruiting	IFCT	Phase 2	Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as immunotherapy with maintenance therapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
NCT02117167 ↗	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients	Active, not recruiting	Intergroupe Francophone de Cancerologie Thoracique	Phase 2	Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as immunotherapy with maintenance therapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
NCT02117167 ↗	SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients	Active, not recruiting	UNICANCER	Phase 2	Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in Non-squamous patients and erlotinib in squamous cells, targeted substudy 1) as well as immunotherapy with maintenance therapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).
NCT02127710 ↗	A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)	Completed	SCRI Development Innovations, LLC	Phase 2	This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.
NCT02127710 ↗	A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)	Completed	AstraZeneca	Phase 2	This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated. An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.

Clinical Trial Conditions for Savolitinib

Condition Name

Condition Name for
Intervention	Trials
Non-small Cell Lung Cancer	5
Carcinoma	3
Healthy Male Subjects	2
Non-small Cell Lung Cancer Metastatic	2

Condition MeSH

Condition MeSH for
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	10
Carcinoma	6
Carcinoma, Renal Cell	6
Lung Neoplasms	4

Clinical Trial Locations for Savolitinib

Trials by Country

Trials by Country for
Location	Trials
United States	122
Canada	17
Korea, Republic of	8
China	8
France	6

Trials by US State

Trials by US State for
Location	Trials
New York	9
California	9
Texas	8
Maryland	7
Illinois	7

Clinical Trial Progress for Savolitinib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	15
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Not yet recruiting	11
Recruiting	8
Completed	7

Clinical Trial Sponsors for Savolitinib

Sponsor Name

Sponsor Name for
Sponsor	Trials
AstraZeneca	18
Hutchison Medipharma Limited	6
Parexel	5

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	30
Other	18
NIH	3